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Abstract
The treatment effects of the same therapy observed from multiple clinical
trials can be very different. Yet the patient characteristics accounting for the
differences may not be identifiable in real practice so that it is necessary to
estimate and report the overall treatment effect for the general popoulation
during the development and validation of a new therapy. The non-linear
structure of the maximum partial likelihood estimates for the (log) hazard
ratio defined with a Cox proportional hazard model leads to challenges in
the statistical analyses for combining such clinical trials. In this paper, we
formulated the expected overall treatment effects using various modeling as-
sumptions. Then we proceeded to propose efficient estimates together with
a version of Wald test for the combined hazard ratio using only aggregate
data. Interpretation of the methods are provided in the framework of robust
data analyses involving misspecified models.
Keyword: combining survival trials, misspecified models, harmonic average.
1 Introduction
Multiple clinical trials may be performed to validate a newly developed ther-
apy to account for the variability of the targeted patient population. The
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data collected from each individual clinical trial may be used to generate
the efficacy (or safety) estimates for each specific trial as well as the overall
efficacy estimate for the overall population to support the effectiveness of
the therapy. In this paper, we will focus on the analyses of time-to-event
data (t) using Cox proportional hazard models. Let Z = {Z1, . . . , Zk} be
the covariates available for each enrolled patient. Given Z, the proportional
hazard model assumes that the hazard function for a patient from the i-th
(i = 1, . . . ,M) trial can be writtens as
hi(t|Z) = hi0(t) exp(β˜′iZ),
where hi0(t) is the baseline hazard function of the i-th trial with unknown
formulation, β˜i = {βi1, . . . , βik} is the vector of log hazard ratios defined
specifically for the patients enrolled in the i-th trial.
Efficient estimates of the trial specific β˜i based on maximal partial likehood
(MPLE) were well developed since the days of Cox (1972, 1975). In this
paper, we are more interested in the methods for statistical inference based on
the information contained in the pooled data from all M trials. Meta analyses
were invented to address such needs. Yuan (2009) provided a comprehensive
review of the statistical methods used to generate an overall (log) hazard
ratio estimate based on multiple clinical trials. The convex combination of
all the log hazard ratio estimates from each individual trial is a popular choice
(Wei, Lin and Weissfeld 1989):
βˆLj =
M∑
i=1
wiβˆij, ∀w1 + . . .+ wM = 1. (1)
Here βˆij (j = 1, . . . , k) denotes the MPLEs of βij derived from the patient
data collected from the i-th trial. The weights wi can be arbitrary constants
sum up to unity, among which the inverse variance scheme may be the most
popular option due to the obvious advantage of minimized variance among
the family of all convex combinations of βˆij’s. Though less common, some
researchers also recommend using the linear combination of the hazard ratio
estimates for any given covariate value Zj:
bˆLj =
M∑
i=1
wie
βˆi,jZj ,∀w1 + . . .+ wM = 1. (2)
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To account for the differences in each βˆij due to randomness inherited from
the observed data, DerSimonian and Laird (1986) provided an overall treat-
ment effect estimate based on random effect models. Yuan continued to
propose a meta-ANOVA model and a meta-polynomial model to address the
differences in βˆij’s due to mis-match of baseline information from different
trials. These methods require a large number of trials (M) to support the
regression algorithms. Here we are only interested in the cases where very
limited number (M ≥ 2) of trials are deliverable.
As far as we know from the research literature, all the statistical models de-
veloped for meta-analyses assume that there exists a set of “true” baseline
hazard function h0i(·) as well as a unique “true” log hazard ratio (vector)
β˜ through out all the trials designed for the same therapy. The baseline
h0i(·) may vary by i, while β˜ has to be consistent for all the M trials. The
differences in the estimated log hazard ratios βˆi = {βˆi1, . . . , βˆik} are either
attributed to the randomness of the observed outcomes or the incomplete-
ness of the covariate data. However, in some cases, such assumptions may be
far from the truth. The treatment effect on different populations may be es-
sentially different due to discrepancies in some latent patient characteristics.
The problem is even more acute if the therapy under investigation targets
specific gene expressions. The human genome is overwhelmingly complex
such that even the most well devised targeted treatment can be subject to
unexpected impacts from genes outside the targeted region. Hence the true
values of β˜i’s may vary with i because the patient populations enrolled for
different trials are in fact heterogeneous with regard to their responses to
the therapy. Even though the inclusion/exclusion criteria and the design of
these trials may appear to be perfectly aligned, it cannot help to suppress
the differences in the patients recruited for different trials. It is impossible to
adjust the hazard ratio estimates for these latent controlling factors because
they are usually unknown to the researchers or not able to be detected by any
currently available technology/assay. Instead, the researcher has to compro-
mise with an overall treatment effect estimate derived from the pooled data,
or from the summary statistics reported for each trial if patient line data are
not available.
Mehrotra et. al. (2012) investigated the effect of deviation from the con-
stant hazard ratio assumption underlying the standard stratified survival
analyses. Our method proposed in this paper can be used to establish an
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efficient overall treatment effect estimate covering multiple stratums of high
variability. Denne et. al. (2014) and Li (2014) provided another good exam-
ple illuminating the necessity of considering different treatment effects (β˜i)
for different trials. One version of an assay may be used to enroll patients by
a biomarker for a validation trial. Another version of the assay targeting the
same biomarker may be needed when the treatment is ready for marketing
due to advances of technology or solely to reduce the cost and time for pa-
tient screening. The two versions of the assay may not perfectly match with
each other. The discrepancies in the test results may reflect some differences
in the patient’s biological profile which are not intended to be captured by
either assay. Such differences may affect the patient responses to the ther-
apy. Hence the intent-to-treat patient population is divided into multiple
subgroups with different assay result combinations. It is reasonable to as-
sume that the patient responses to the same targeted treatment are in fact
different (or even opposite as was observed in some real life examples) across
these subgroups defined by both assays (Sargent et. al. 2005). However, only
the market-ready version of the assays will be available to the patients/client
laboratories so that it is the overall treatment effect covering all subgroups,
rather than the treatment effect on patients with specific test result combi-
nations, that concerns the developer.
The linear estimate βˆL defined by (1) or bˆL by (2) was used as the estimator
for the overall treatment effect in these mentioned publications. The linear
estimates has its own merit. It is easy to be implemented for calculation
and the derivation of its variance is straightforward. It is guaranteed to be
close to the correct answer if the true β˜i values across different trials only
differ by a small amount of no practical significance. However, if the β˜i’s are
very different, despite the choice of the weights (wi), the usage of a linear
estimate is not mathematically justifiable because each component of the
linear combination converges to a completely different βij. It is not very
likely that the limit of the estimator (
∑
wiβˆij) is an exact measurement of
the overall treatment effect because the (log) hazard ratio defined by the Cox
proportional hazard model is obviously nonlinear with regard to the observed
survival times. As a matter of fact, we will show that in most cases βˆL (and
bˆL) defined by the inverse variances coefficients or by the proportion of trials
sizes leads to over estimate of the true overall hazard with the treatment.
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The major concerns and challenges for a pharmaceutical researcher facing
data collected from multiple trials can be summarized by two questions.
First, what is the proper definition of the overall treatment effect? Hazard
ratio is very different from the other commonly used endpoints such as the
mean/median survival time and response rate. The later resorts to a natural
measurement (in most cases, counting) of observed events or time, while haz-
ard ratio is an artificial concept specifically invented for the Cox proportional
hazard model. The definition of a “hazard ratio for the overall population”
is ambiguous now that the Cox model is no more applicable to a mixed pop-
ulation. In the ideal case one may have all the exact knowledge about the
true underlying performance of the therapy including but not limited to the
shapes of the baseline hazards hi0(t) and the values of the log hazard ratios
β˜i. That being said, the overall treatment effect is not a readily defined value
as a unique functional of all such baseline functions and parameters. For the
first time in the literature, we point out that the problem has to be addressed
in the misspecified model framework. Typically the target to be estimated
with a misspecified model is the limit of a chosen estimator. Its definition
has to depend on the modelling assumptions chosen by the researchers. We
will demonstrate two kinds of such definitions in this paper and provide ex-
plaination for their very delicate differences. The second question naturally
comes after the first one, i.e., how to generate a statistically efficient esti-
mate for the overall drug efficacy after a proper definition? It is even more
challenging if patient line data are not available but only aggregate statistics
can be accessed for some of the trials.
2 Combined hazard ratio as a limit of the
MPLE from pooled data
It is sufficient to consider only two independent trials. Generalization of the
results to cover more trials is straightforward. Assume that n patients were
enrolled for the first clinical trial. The survival times and baseline demo-
graphics of the patients are denoted X = {(Xi, δi,Zi), i = 1, . . . , n}. Here Xi
is the right-censored survival time of the i-th patient, δi = 0/1 indicates that
Xi is censored or an observed event time, Zi is a k-dimensional covariate with
probability density function fZ(z1, . . . , zk). In many cases the distribution fZ
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may vary by the trials. For simplicity, we assume the same distribution fZ
for all the trials in this paper. Extension of our methods to accommodate
different distributions for the covariates is obvious. Assuming independent
censoring, the patients’ survival times are i.i.d.’s with proportional hazard
hX(x|Z) = hX0(x) exp(α˜′Z).
By definition, the pdf of an uncensored Xi (i.e., δi = 1) conditioned on Zi is
hX0(x) exp(α˜
′Z)e− exp(α˜
′Z)HX0(x),
where hX0(·) is an arbitrary baseline hazard function of the first trial and
HX0(x) =
∫ x
0
hX0(u)du is the corresponding culmulative hazard. Similar
notations can be defined for the second trial. Let Y = {(Yj, δj,Zj), j =
1, . . . ,m} be the data collected from the second trial. Assuming proportional
hazard and independent censoring, the patients from the second trial has
hazards
hY (y|Z) = hY 0(y) exp(β˜′Z).
The trial-specific treatment effect estimates (αˆ and βˆ) and their asymptotic
variance-covariance matrices can be easily estimated using the MPLEs cal-
culated from the X and Y data respectively. We are particularly interested
in the setup where the underlying true values of α˜ 6= β˜. Without loss of gen-
erality, let the first component of the covariates (Zi1) be the arm indicator
for the i-th patient. The patient is in the treatment arm if Zi1 = 1 or he is
in the control arm if Zi1 = 0. The value of α1 and β1, the first component
of the regression parameter α˜ and β˜ respectively, are of most concern as a
measurement of the treatment effect. It is convenient to assume α1 < β1 for
all the discussions presented in this paper.
It is natural to consider the pooled patient line data
{(Wi, δi,Zi), i = 1, . . . , n+m}
= {(Xi, δi,Zi), i = 1, . . . , n} ∪ {(Yj, δj,Zj), j = 1, . . . ,m}.
Most researchers consider the MPLE calculated from all n+m (denoted by
N) pooled patient line (PL) records not only as an appropriate estimate for
the overall treatment effects but also the best (especially when compared to
the linear estimates βˆL or bˆL) answer to our first question. The only obvious
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drawback of the MPLE is that it requires the knowledge of all N patient line
data:
θˆPL = arg max
θ˜
n+m∏
i=1
[
exp(θ˜′Zi)∑
j∈<i exp(θ˜
′Zj)
]δi
, (3)
where <i is the set of labels for those patients (originally from X or Y) who
are at risk at time Wi−.
The overall log hazard ratio θ˜ is hence defined as the limit of θˆPL when both
n and m → ∞. It is worth to point out that one needs to first determine
what is an appropriate statistic for the overall treatment effect based on both
statstical and clinical thinking. Then the parameter to be estimated follows
as the limit of the statistic, not vice versa. A different version of the overall
treatment effect can be as valid based on other assumptions about the esti-
mating procedure. We will extend the discussion to provide such an example
in the Section 4.
It is equivalent to imposing a misspecified Cox model (working model) on
the pooled data such that the combined hazard can be written as
hW (w|Z) = hW0(w) exp(θ˜′Z). (4)
Assume that the two trials have the same baseline hazard hX0(t) = hY 0(t) =
h0(t) for all t > 0 because the control arms are usually subject to standard
of care. Such treatments are well established for the general population.
The true pdf of the pooled data Wi is a mixture of two proportional hazard
models
ph0(w)e
α˜′Ze− exp(α˜
′Z)H0(w) + (1− p)h0(w)eβ˜′Ze− exp(β˜′Z)H0(w),
where n/(n + m) → p as n,m → ∞ is a fixed ratio of the sample sizes
controlled by the researcher. The true model for Wi does not satisfy the
proportional hazard assumption:
h(w|Z) = h0(w)pe
α˜′Ze− exp(α˜
′Z)H0(w) + (1− p)eβ˜′Ze− exp(β˜′Z)H0(w)
pe− exp(α˜′Z)H0(w) + (1− p)e− exp(β˜′Z)H0(w) .
The formulation of the limit of θˆPL can be studied using the techniques
developed for misspecified models in Struthers and Kalbfleisch (1986) and Lin
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and Wei (1989). Let hi(t) be the true hazard function of the i-th patient from
the pooled dataset W and Ri(t) = 1Wi≥t be the at-risk process at arbitrary
time t > 0, i = 1, . . . , n+m. It is convenient to define the notations following
the convention of Andersen and Gill (1989), Struthers and Kalbfleisch (1986)
and Lin and Wei (1989):
s(0)(t) = E
[
N∑
i=1
Ri(t)hi(t)
]
, s(1)(t) = E
[
N∑
i=1
Ri(t)hi(t)Zi
]
,
s(0)(θ˜, t) = E
[
N∑
i=1
Ri(t)e
θ˜′Zi
]
, s(1)(θ˜, t) = E
[
N∑
i=1
Ri(t)e
θ˜′ZiZi
]
.
Here the expected values are defined with respect to the true distribution of
Wi and Zi.
Proposition 1. (based on Theorem 2.1 of Lin and Wei (1989)) Let θˆPL be
the MPLE of the log hazard ratios for the overall treatment effect as defined
in (3). When n,m→∞, θˆPL converges in probability to the unique solution
of the following equation:∫ ∞
0
s(1)(t)dt−
∫ ∞
0
s(1)(θ˜, t)
s(0)(θ˜, t)
s(0)(t)dt = 0. (5)

Without censoring it follows the definition of Ri(t) and the hazard hi(t) that
E[Ri(t)hi(t)|Zi] = P [Wi ≥ t|Zi]hi(t).
The right hand side of the above formula is simply the pdf of Wi by the defini-
tion of the hazard hi(·). It can be written as fX(t|Z) or fY (t|Z) respectively,
in the form of
h0(t) exp(α˜
′Zi)e− exp(α˜
′Zi)H0(t) or h0(t) exp(β˜
′Zi)e− exp(β˜
′Zi)H0(t)
depending on whether the i-th patient is from the first or the second trial.
Hence s(0)(t) and s(1)(t) can be simplified by the following calculation
E[Ri(t)hi(t)] = E[E[Ri(t)hi(t)|Zi]]
= EZ[fX(t|Z)] if Wi ∈ X, EZ[fY (t|Z)] otherwise.
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Similarly s(0)(θ˜, t) and s(1)(θ˜, t) can be simplified using E[Ri(t)|Zi] = P [Wi ≥
t|Zi] in the form of
e−H0(t) exp(α˜
′Zi) or e−H0(t) exp(β˜
′Zi).
Expand the shorthand notations defined for Proposition 1, we have
s(0)(t) = E[nfX(t|Z) +mfY (t|Z)],
s(1)(t) = E[nfX(t|Z)Z +mfY (t|Z)Z],
s(0)(θ˜, t) = E[nP (X ≥ t)eθ˜′Z +mP (Y ≥ t)eθ˜′Z],
s(1)(θ˜, t) = E[nP (X ≥ t)eθ˜′ZZ +mP (Y ≥ t)eθ˜′ZZ].
All the above notations turn out to depend on no random variables other
than the covariate Zi’s. The subscripts for Z are suppressed with the as-
sumption that the Zi’s are independent and identically distributed. Under
mild smoothness conditions, the first term of equation (5) can be simplified
by switching the order of the integrals:∫ ∞
0
s(1)(t)dt = E
[
n
∫ ∞
0
fX(t|Z)dtZ +m
∫ ∞
0
fY (t|Z)dtZ
]
= NE(Z).
Plug in (5) with the definitions of the pdf’s and survival functions. For suf-
ficiently large n and m, substitute n/(n+m) by p, i.e., the fixed ratio of the
study sizes. Eliminate H0(t) by letting u = H0(t) and hence du = h0(t)dt.
We derived an equation for the definition of the overall treatment effect.
Corollary 1.1 Assume no censoring in the data X and Y. The true treat-
ment effect (log hazard ratios) from either trials are known and denoted by
α˜ and β˜ respectively. The overall log hazard ratio θ∗PL defined as the limit of
θˆPL with n,m→∞ is the unique solution to the following equation:
E(Z) =
∫ ∞
0
pE
(
eθ˜
′Z−exp(α˜′Z)uZ
)
+ (1− p)E
(
eθ˜
′Z−exp(β˜′Z)uZ
)
pE
(
eθ˜′Z−exp(α˜′Z)u
)
+ (1− p)E (eθ˜′Z−exp(β˜′Z)u) · (6)[
pE
(
eα˜
′Z−exp(α˜′Z)u
)
+ (1− p)E
(
eβ˜
′Z−exp(β˜′Z)u
)]
du.

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The distribution of the covariates Z can be well approximated using data
from the general intent-to-treat population. Once the distribution of Z is
known, equation (6) can be solved numerically.
Usually one needs all N patient line data to define the MPLE θˆPL as well as
its sandwich-type robust variance estimate. Nonetheless, if only aggregate
data such as the MPLEs αˆ and βˆ from individual trials are available for
some reason, one may solve equation (6) with α˜ and β˜ substituted by their
estimates αˆ and βˆ. The solution to such an equation, which is henceforth
denoted by θˆM (the subscript M stands for “misspecified model”), does not
rely on the knowledge of the baseline hazard h0(·). It is a semiparametric,
asymptotically efficient estimate to θ∗PL because the MPLEs αˆ and βˆ are
based on maximum likelihoods. Such procedures are well known for being
invariant with regard to functional transformations.
The condition of no censoring in Corollary 1.1 is natural for the definition
of θ∗PL because we are only interested in the performance of the therapy.
Censoring is considered as noise imposed on the observed survival times and
should be excluded from the estimating procedure if at all possible. The
MPLEs αˆ and βˆ reported for the individual trials are (asymtotically) unbi-
ased for the underlying log hazard ratios α˜ and β˜ even if the data X and
Y are censored. Therefore θˆM always remains an unbiased estimate for the
overall treatment effect θ∗PL no matter the data are censored or not.
Example 1. Usually the effects of the covariates are assumed to be sorted
out by proper randomization. One of the most important analysis used in
practice use the treatment arm indicator Z = 0/1 as the only covariate
with q = P (Z = 1). Denote the hazard ratio of the first trial by a = eα,
the hazard ratio of the second trial by b = eβ. By corollary 1.1, the MPLE
cˆPL = Exp(θˆPL) calculated from the uncensored pooled line data ofN patient
records converges to the solution of the following equation about c:
1 =
∫ ∞
0
(1− q)e−u + pqae−au + (1− p)qbe−bu
(1− q)e−u + pqce−au + (1− p)qce−bu · (7)[
pce−au + (1− p)ce−bu] du.
Equation (7) can be simplified after a series of basic algebraic transforma-
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tions:
1 =
∫ ∞
0
(1− q)e−u + pqae−au + (1− p)qbe−bu
(1− q)e−u + pqce−au + (1− p)qce−bu · e
−udu (8)
It is easy to see that the right-hand-side of (8) is a strictly decreasing, convex
function of c. It implies that the overall hazard ratio defined by the solu-
tion c∗PL to equation (8) must take a value on the open interval (a, b). In
Appendix 5.2, we will also show that in most cases c∗PL is superior to (i.e.,
smaller than) the linear alternative exp[pα+ (1− p)β] and pa+ (1− p)b. 
Now take a closer look at θˆPL. It is conventionally considered as the best
estimate to the overall log hazard ratio of the combined trials. However, θ∗PL
is actually defined to be the limit of the uncensored θˆPL. The estimator θˆPL
is subject to the impact of censoring and can be biased for θ∗PL. By (6), the
value of θ∗PL only relies on α˜, β˜ and the distributions of Z.
Corollary 1.2 Assume independent right censoring for both X and Y such
that the survival function of the censoring times are denoted CX(t|Z) and
CY (t|Z) respectively. The limit of θˆPL with n,m→∞ is the unique solution
to the following equation with respect to θ˜ with known values of α˜ and β˜:∫ ∞
0
E[pfX(t|Z)CX(t|Z)Z + (1− p)fY (t|Z)CY (t|Z)Z]dt = (9)
∫ ∞
0
pE
(
eθ˜
′Z−exp(α˜′Z)H0(t)ZCX(t|Z)
)
+ (1− p)E
(
eθ˜
′Z−exp(β˜′Z)H0(t)ZCY (t|Z)
)
pE
(
eθ˜′Z−exp(α˜′Z)H0(t)CX(t|Z)
)
+ (1− p)E (eθ˜′Z−exp(β˜′Z)H0(t)CY (t|Z)) ·
[pE (fX(t|Z)CX(t|Z)) + (1− p)E (fY (t|Z)CY (t|Z))] dt. .

With a mixed population, censoring contains information about the source of
the data, which is correlated with the length of the subject’s expected survival
time beyond censoring. The limit of θˆPL must contain all such information
as the censoring mechanism CX(t|Z), CY (t|Z) and the baseline hazard H0(t).
Example 2. Assume the same setup as in Example 1. The survival times
observed from either trials follow Cox models defined with a treatment arm
indicator Z ∼ Bernoulli(q). Both clinical trials will be terminated at given
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time Tmax > 0. Hence the censoring time has a point mass of unity at Tmax.
That is, CX(t|Z) = CY (t|Z) = 1 if t < Tmax and 0 otherwise. Expand
the definitions of the distribution functions and use the change-of-variable
technique by letting u = H0(t) in equation (9), it becomes
1− e−H0(Tmax) =
∫ H0(Tmax)
0
(1− q)e−u + pqae−au + (1− p)qbe−bu
(1− q)e−u + pace−au + (1− p)qce−bu · e
−udu.
(10)
The limit of the MPLE θˆPL calculated from the censored line data is the
solution c∗ to the above equation. To study the bias in θˆPL, we need to
compare c∗ against c∗PL, which is the solution to equation (8). For simplicity,
denote the integrand in equation (10) by g(u|c) for fixed a and b. Equation
(8) asserts that g(u|c∗PL) is a well defined pdf because its integral on (0,∞)
equals unity. Consider the fact that c∗PL < pa + (1− p)b (Appendix 5.2). It
is easy to prove that the fraction term
(1− q)e−u + pqae−au + (1− p)qbe−bu
(1− q)e−u + pac∗PLe−au + (1− p)qc∗PLe−bu
> 1
if 0 < u < [ln(1−p)(c∗PL−b)/p/(a−c∗PL)]/(b−a) and it is less than 1 otherwise.
Hence the pdf g(u|c∗PL) only intersects a standard Exponential pdf e−u at
one point, which in turn implies that the distribution defined by g(u|c∗PL)
is stochastically smaller than a standard Exponential distribution (Fill and
Machida 2001). Therefore, the cdf corresponding to g(u|c∗PL) is always bigger
than that of the standard Exponential distribution
∫ H
0
e−udu = 1− e−H for
any given H:
1−e−H0(Tmax) <
∫ H0(Tmax)
0
(1− q)e−u + pqae−au + (1− p)qbe−bu
(1− q)e−u + pac∗PLe−au + (1− p)qc∗PLe−bu
·e−udu.
Note that g(u|c) is monotonically decreasing with respect to c. To make an
equality as in equation (10), its solution c∗ must be greater than c∗PL. When
the survival time data are censored at a maximum allowable trial length
Tmax, θˆPL is always associated with a positive bias. The bias decreases with
Tmax. 
Corollary 1.2 indicates that the most accepted MPLE θˆPL is not robust
against variability in the treatment effects observed from multiple trials.
Hence we recommend reporting the overall log hazard ratio for multiple trials
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using θˆM rather than θˆPL. The former is not only robust (unbiased despite
of censoring) but also provides better chance for the researchers because it
only requires aggregate statistics from each sub-population of concern. The
following example illustrates the impact of censoring on θˆPL using simulated
data.
Example 3. We performed 1000 rounds of independent simulations to mimic
the following scenario: the survival times of 200 patients treated in the first
trial follow an Exp(0.3) distribution. With 1:1 randomization (i.e., q = 0.5),
another 200 patients in the control group has survival times sampled from a
standard exponential distribution Exp(1). Let p = 0.7, the second trial en-
rolls 85 patients for the treated group and 85 patients for the control group.
To mimic a lower drug efficacy, the survival times of the treated patients
from the second trial are sampled from an Exp(0.8) distribution, while the
survival times of the control group patients are sampled from Exp(1).
Without censoring, we can calculate θˆPL for each of the 1000 simulated data
set and summarize the distribution of θˆPL using its empirical distribution. In
this example, it was reported that E(θˆPL) = −0.926 (equivalent to ln(0.396))
with a 95% confidence interval of (−1.088,−0.756). According to Corollary
1.1 this is an (asymtotically) unbiased estimate for the true overall log hazard
ratio θ∗PL as there is no censoring.
We continued to censor the 1000 simulated data sets using various censoring
time Tmax ∈ [1, 10] and tried to calculate the estimates θˆM and θˆPL respec-
tively for each specific Tmax. In Figure 1(i) θˆM ’s are reported as the solution
to equation (8) with α and β substibuted by αˆ and βˆ, which are calculated
from the censored trial 1 and trial 2 data respectively. On the other hand, in
Figure 1(ii) the MPLE θˆPL’s are calculated using (3) with all 570 censored
line data from either trials pooled together.
The gray lines in Figure 1 outline the true overall hazard ratio (-0.926) and
its 95% confidence interval (−1.088,−0.756). The bias of θˆPL can be easily
observed in Figure 1(ii). When the trials are censored at Tmax = 1, about 51%
of the collected data are censored. The MPLE θˆPL reported for this scenario
has a mean of -0.854 and a 95% confidence intervals of (−1.074,−0.601). It
accounts for about 7.8% of positive bias in the log hazard ratio estimates.
Such a result can be of serious concern for those clinical trials expected to
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Figure 1: (i) Mean and the 95% CI for θˆM . (ii) Mean and the 95% CI for
θˆPL.
be associated with low event rates, e.g., a trial for breast cancer treatments.
For the same censored dataset, θˆM displayed in Figure 1(i) appears to be
unbiased for θ∗PL. The confidence interval of θˆM tends to be wider with more
data being censored because the variance of the log hazard ratio estimate
is proportional to the inverse of the number of observed events (Kalbfleisch
and Prentice (2002)). 
3 Combined hazard ratio via harmonic means
We noted that θˆPL and θˆM are semi-parametric estimators without requiring
any knowlege about the baseline. However, the baseline hazard hW0(·) of the
misspecified model (4) is different from the baseline hazard h0(·) defined for
each individual clinical trial. It is due to the fact that the MPLE procedure
is the result of simultaneous maximization of the unknown parameter θ˜ and
the discretized baseline hazard hW0(·) in the form of a Breslow hazard esti-
mate (Breslow (1972), Johansen (1983)). The shape of the baseline hazard
h0(·) is twisted to fit the mixed event times and in return leads to a slightly
under-estimated therapy effect, or equivalently an over-estimated log hazard
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ratio θ˜∗PL in many cases. We will propose another method to avoid such
undesirable effect.
Example 4. Let X1, . . . , Xn ∼ Exp(a) and Xn+1, . . . , X2n ∼ Exp(1) be the
i.i.d. event times observed from the treatment and control groups of the first
trial, Y1, . . . , Ym ∼ Exp(b) and Ym+1, . . . , Y2m ∼ Exp(1) be the event times
recorded from the treatment and control groups of the second trial. Without
loss of generality, assume a < b < 1. No censoring is allowed for simplicity.
Provided the complete patient line data, it is easy to estimate the treatment
effects of the therapy in either clinical trial using the MLEs aˆ = n/
∑n
i=1Xi
and bˆ = m/
∑m
j=1 Yj. Assuming a misspecified Exp(c) model for the pooled
data, it is natural to estimate the overall treatment effect using
cˆ =
n+m∑n
i=1Xi +
∑m
j=1 Ym
=
1
n/(n+m)aˆ+m/(n+m)bˆ
p−→ 1
p/a+ (1− p)/b.
Again, the overall hazard ratio can be defined as the limit of the chosen
estimate cˆ. It turns out to be the harmonic mean of the individual trial
effects a and b weighted by the ratio of the study sizes p : (1 − p). As a
matter of fact, the harmonic mean effect is smaller than that defined by the
semiparametric MPLE method in most cases (Appendix 5.2):
1
p/a+ (1− p)/b < c
∗
PL, if a < b < 1,
where c∗PL is the solution of equation (8) as well as the limit of the MPLE
exp(θˆPL) calculated using {W1, . . . ,W2n+2m} = {X1 . . . , X2n, Y1, . . . , Y2m}
without assuming an underlying exponential hazard. The difference between
the two versions of the overall treatment effect estimate can be attributed to
a twisted baseline hazard hW0(·) approximate due to the MPLE procedure.
Consider the two trials respectively, the Breslow hazard estimates
Hˆ0(t) =
∑
i:Xi≤t
1∑2n
`=1RX`(Xi)aˆ
Z`
or
∑
j:Yj≤t
1∑2m
`=1RY `(Yj)bˆ
Z`
calculated from either sets of patient line data are both asymptotically un-
biased for the true underlying linear culmulative hazard function H0(t) = t.
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Here the only covariate Z` = 0 if the patient is in the control group and 1
if the patient is in the treatment group. The numerator of the fraction is
always equal to one because there are no censoring. However, the Breslow
estimate calculated from the pooled data Wi’s does not lead to a constant
hazard estimate over time. At arbitrary time t, the non-parametric baseline
hazard hW0(t) as a limit of the Breslow estimate is
hW0(t) =
pe−ata+ (1− p)e−btb+ e−t
[pe−at + (1− p)e−bt]c∗PL + e−t
. (11)
The derivation of the above formula is provided in Appendix 5.1. Note that
hW0(0) =
pa+ (1− p)b+ 1
c∗PL + 1
and hW0(∞) = a
c∗PL
.
Unless a = b, the shape of hW0(t) is tilted to the right by the fact that
pa + (1 − p)b > c∗PL and a < c∗PL (Appendix 5.2). For sufficiently large t,
hW0(t) is monotonically decreasing and hW0(t) = 1 happens at only one time
point t. The trend in hW0(t) is consistent with the monotone changes in
the mixture proportion of the complete population. At the very beginning,
the estimated baseline hazard is bigger than one. The proportion of treated
patients from the first trial increases with time because the patients from the
second trial have shorter expected life (a < b) and finally the baseline hazard
estimate is dominated by a, the effect of the first trial, and scaled by 1/c∗PL
such that the average baseline hazard is close to one. Hence a smaller com-
bined effect (i.e., bigger hazard ratio c∗PL) is given by the MPLE procedure
compared to the harmonic mean effect based on the parametric Exponential
model. In a sense, the MPLE procedure is an overfit to the data if the re-
searcher is confident about the fact that the control groups from either trial
are not essentially different. 
It is curious to see that the harmonic mean type of definition for the com-
bined trial effect can be extended to address statistical models assuming
much more general conditions where neither the underlying exponential dis-
tribution nor the univariate covariate structure is needed. Let X denote the
observed survival times of n patients recruited for a clinical trial. Their
uncensored survival times follow a proportional hazard model with haz-
ard hX(t|Z) = h0(t) exp(α˜′Z). Similarly, the survival times (Y) of another
m = n(1−p)/p patients recruited for a second trial also follow a proportional
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hazard model with the same baseline hazard h0(t) and a log hazard ratio β˜.
Here α˜ is a k-variate vector of the same structure as β˜ but of different values.
The formulation of the baseline hazard h0(t) is unknown. The MPLE is not
appropriate for the estimation of the log hazard ratio (θ˜) for the combined
population if one needs to avoid a twisted baseline hazard. Instead, we set out
to define the MLE for θ˜. It leads to a different version of a semi-parametric
estimate (θˆHM , where the subscript HM stands for “harmonic mean”) for
the overall log hazard ratio. It is based on aggregate statistics only. Patient
line data are not required for the realization of θˆHM .
Proposition 2. Let θˆMLE be the maximum likelihood estimate (MLE) for
the overall log hazard ratio θ˜ when a proportional hazard model with the
following pdf is fitted to the pooled N = n+m surival time records:
f(t; θ˜|Z) = h0(t)eθ˜′Ze− exp(θ˜′Z)H0(t), t ≥ 0. (12)
When n,m→∞, θˆMLE converges in probability to a constant θ∗HM , which is
the unique solution to the following equation with respect to θ˜:
E(Z) = E
[
eθ˜
′ZZ
(
p
eα˜′Z
+
1− p
eβ˜′Z
)]
. (13)
Proof. Again, we assume no censoring when trying to define the “true” values
of the overall treatment effect because no information other than the mea-
surements of the treatment effect should be of concern. Such conditions can
be loosen when we get to the discussions about the estimating procedures
for the treatment effects established here.
Assuming the misspecified proportional hazard model (12), the joint pdf of
the N observed survival times is
N∏
i=1
h0(Ti)e
θ˜′Zie−e
θ˜′ZiH0(Ti).
The derivative (w.r.t. θ˜) of the logarithm of the misspecified joint pdf is
∇θ˜`(T1, . . . , TN ,Z1, . . . ,ZN) =
N∑
i=1
Zi − eθ˜′ZiZiH0(Ti).
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By the law of large number,
∇θ˜`(T1, . . . , TN ,Z1, . . . ,ZN)/N
p−→ Emix
[
Z− eθ˜′ZZH0(T )
]
,
where Emix(·) stands for the expectation defined in terms of the true mixed
model with pdf fmix:
fmix(t, z) = [ph0(t)e
α˜′ze−e
α˜′zH0(t) + (1− p)h0(t)eβ˜′ze−eβ˜
′zH0(t)]fZ(z).
This is a typical setup of an estimating equation. Under mild regularity
conditions, it can be proved that the MLE θˆ defined by the solution to the
equation ∇θ˜` = 0 converges in probability to a θ˜HM , which is the solution to
Emix
[
Z− eθ˜′ZZH0(T )
]
= 0. (14)
Detail discussions about the asymptotics of the MLE derived from misspec-
ified models are available in White (1982). Note that (14) is equivalent to
Emix(Z) = Emix
[
eθ˜
′ZZH0(T )
]
= EZ
[
Emix
(
eθ˜
′ZZH0(T )|Z
)]
= EZ
[
eθ˜
′ZZEmix(H0(T )|Z)
]
. (15)
To simplify the right hand side of (15), we calculate
Emix[H0(T )|Z]
=
∫ ∞
0
H0(t)fmix(t|Z)dt
=
∫ ∞
0
H0(t)
[
ph0(t)e
α˜′Ze−e
α˜′ZH0(t) + (1− p)h0(t)eβ˜′Ze−eβ˜
′ZH0(t)
]
dt
=
∫ ∞
0
u
[
pae−au + (1− p)be−bu] du
= p/a+ (1− p)/b.
Note that h0(t)dt = dH0(t). The third line of the above equation was due
to the following definition of notations: H0(t) = u, e
α˜′Z = a and eβ˜
′Z = b.
Equation (13) follows (15) with the definition of Emix[H0(T )|Z] plugged in. 
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Following the discussions about misspecified models in White (1982) and
Akaike (1973), it can be seen that equation (14) actually defines θ∗HM as the
maximizer of the following expectation:
Emix[ln(f(T ; θ˜|Z)fZ(Z))].
Hence, θ∗HM has an obvious geometric interpretation. It minimizes the Kullback-
Leibler distance between the candidate working models f(t; θ˜|Z) and the true
model fmix(t|Z):
θ∗HM = arg min
θ˜
D[fmix, f(t; θ˜)]
= arg min
θ˜
Emix[ln(fmix(T,Z))]− Emix[ln(f(T, θ˜,Z))].
Now we have another version of the definition for the overall log hazard ra-
tio θ∗HM . It can be slightly smaller than θ
∗
PL in most cases (Appendix 5.2).
Both of these two numbers are valid measurements of the treatment effect
on the combined population, though they are based on different modelling
assumptions. We consider θ∗HM a number closely related to the harmonic
mean. Such an idea can be illustated by the following example.
Example 5. Assume the same setup as in Example 1. The treatment
group indicator Z ∼ Bernoulli(q) is the only covariate collected for the
enrolled patients. The observed survival times (with or without censoring)
follow proportional hazard models with hazard ratios a = eα and b = eβ
respectively for trial 1 and 2. By equation (13), the overall hazard ratio c∗HM
is the solution to the following equation:
q = E(Z) = E
[
cZZ
(
p
aZ
+
1− p
bZ
)]
= qc
(
p
a
+
1− p
b
)
=⇒ c∗HM =
1
p/a+ (1− p)/b. (16)

Note that exponential survival times are not required in Example 5. The
harmonic type of calculation (16) is applicable to any general proportional
hazard modelling setup.
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Substitute α and β by the corresponding MPLEs αˆ and βˆ in equation (13).
Solve the estimating equation about θ˜ and denote the solution by θˆHM . It is
an asymtotically efficient estimate for θ∗HM because both αˆ and βˆ are based
on maximum likelihood principles and hence are invariant to any functional
transformations. The asymptotic variance of θˆHM can be derived using the
delta method. Consider θˆHM as an implicit function of αˆ and βˆ by the es-
timating equation (13). Let ∂j θ˜ = (∂θ1/∂αj, . . . , ∂θk/∂αj), ∀j = 1, . . . , k.
Assuming mild regularity conditions, e.g., dominated convergence for the
variables defined in (13), one may switch the order of integrations and dif-
ferentiations. The values of ∂j θ˜ can be calculated by solving the following
linear system about ∂j θ˜:
E
[
eθ˜
′ZZ
(
p
eα˜′Z
+
1− p
eβ˜′Z
)(
Z′∂j θ˜
)]
= E
[
eθ˜
′ZZ
pZj
eα˜′Z
]
.
Similarly it is easy to derive the formulas for (∂θ1/∂βj, . . . , ∂θk/∂βj), ∀j =
1, . . . , k. Usually the variance-covariance matrices of αˆ and βˆ, denoted by
V ar(αˆ and V ar(βˆ), are reported together with the point estimate values. By
the delta method, the asymtotic variance of θˆHM can be calculated: ∂θ1/∂α1 . . . ∂θ1/∂βk. . .
∂θk/∂α1 . . . ∂θk/∂βk
( V ar(αˆ) 0k×k
0k×k V ar(βˆ)
) ∂θ1/∂α1 . . . ∂θk/∂α1. . .
∂θ1/∂βk . . . ∂θk/∂βk
 .
A wald test can be developed for the values of θ∗HM with its variance-covariance
matrix calculated as above.
Example 5. (cont.) When there is only one Bernoulli covariate Z as was
specified in Example 5, the variance of the log hazard ratio estimate
θˆHM = ln
1
p/ exp(αˆ) + (1− p)/ exp(βˆ)
can be calculated using the delta method:
V ar(θˆHM) =
p2e−2αˆV ar(αˆ) + (1− p)2e−2βˆV ar(βˆ)
(pe−αˆ + (1− p)e−βˆ)2 .
When α = β, the above formula degenerages to V ar(θˆHM) ≈ p2V ar(αˆ)+(1−
p)2V ar(βˆ), implying that θˆHM is equivalent to θˆL = pαˆ+(1−p)βˆ in this case.
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A Wald test for the overall treatment effect H0 : θ
∗
HM = 0 can be defined
using the test statistic θˆ/
√
V ar(θˆHM). 
4 Conclusion
In this paper we investigated various methods for the estimation of the overall
treatment effect observed from a mixed patient population. Linear estima-
tors in the form of θˆL =
∑
iwiβˆi or cˆL =
∑
iwie
βˆi have been the favorite
of many researchers for their simplicity. However, it is not mathematically
justifiable to approximate the notoriously nonlinear hazard ratio using any
linear estimators if the patient responses to the treatment are highly diver-
sified in various sub-groups of the intent-to-treat population. In particular,
we showed that cˆL > exp(θˆL) and both of them are, in most cases, positively
biased for the hazard of the combined treated patients.
We propose that an appropriate definition of the overall treatment effect for
a mixed population should be first of all based on an estimating procedure
that is justifiable from either a clinical or statistical perspective. The first
candidate meets such criterion is the MPLE θˆPL calculated from the pooled
patient line data. It converges to a well-defined overall log hazard ratio θ∗PL
for the combined trials if the observed event times are not censored. How-
ever, θˆPL is biased if the data are censored as in most of the real life examples.
The MPLE θˆPL has a robust version θˆM defined with a misspecified pro-
portional hazard model. It is an asymptotically efficient semi-parametric
estimator calculated from the aggregate statistics αˆ and βˆ. It converges to
θ∗PL with increasing sample sizes despite censoring in the data. We noted that
the baseline hazard function is twisted when applying the MPLE procedure
to the observed survival times. To avoid tampering the shape of the non-
parametric baseline hazard, we proposed a harmonic mean type of estimator
θˆHM . Again, it is a semi-parametric estimator based on αˆ and βˆ only. It con-
verges to a θ∗HM , which minimizes the Kullback-Leibler distance between the
true mixed proportional hazard model and the misspecified working model.
The variance-covariance matrix of θˆHM can be calculated using the delta
method and the reported V ar(αˆ) and V ar(βˆ). We also derived a Wald test
for the values of θ∗HM .
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5 Appendix
5.1 Example 4 (cont.)
In Example 4 of section 3, we noted that the MPLE procedure together with
the Breslow estimate can twist the shape of the non-parametric baseline haz-
ard function. Details of the calculations are provided here.
Assume the same Exponential setup delineated in Example 4. At arbitrary
time t > 0, let w be the event time (it can be observed from either trial)
right before t and w+ be the next event time. The Breslow hazard estimate
for the infinitestimal time interval (w,w+) is
dΛˆ0(t) =
1
[nX(t) +mY (t)]cˆPL + (nXc(t) +mY c(t))
, (17)
where nX(t) and mY (t) are the number of treated patients still at risk up to
time t, nXc and mY c are the number of living control group patients. The
formulation of dΛˆ0(t) is discussed in many research papers and texts, e.g.,
Breslow (1972), Kalbfleisch and Prentice (2002) and Hanley (2008), though
the meaning of the formulas remains unclear to many statisticians. It is
corresponding to a discretized Poisson process with constant hazard between
consecutive event times. All history up to time w can be ignored since
the hazard is defined as a conditional probability for the future beyond w.
Consider a control group patient being alive at time w. The estimate dΛˆ0(t) is
in fact an empirical approximate for the probability of observing this control
group patient die within the time interval [w,w+): dΛˆ0(t) = P [Xc ≤ (w+ −
w)], where Xc ∼ Exp(λ0) is the event time of the imaginary control group
patient with a to-be-estimated intensity parameter λ0 specifically defined
for the time interval [w,w+). This is consistent with the definition of the
cumulative hazard:∫ w+
w
λ0(t)dt = ln
S0(w+)
S0(w)
≈ S0(w+)− S0(w)
S0(w)
= P [Xc ≤ (w+ − w)],
where S0(·) denotes the baseline survival function. The length of the time
interval (w+ − w) is also exponentially distributed, according to the true
underlying distribution, with an intensity of
nX(t)a+mY (t)b+ (nXc(t) +mY c(t))
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because each of the nX(t) living treated patients from trial 1, the mY (t)
treated patients from trial 2 and the (nXc(t)+mY c(t)) control group patients
can be considered as a competing risk. Use the joint pdf of two independent
exponential random variables (Xc vs. w+ − w) to calculate that
dΛˆ0(t) = P [Xc ≤ (w+ − w)] = λ0
λ0 + nX(t)a+mY (t)b+ (nXc(t) +mY c(t))
by (17)
=
1
[nX(t) +mY (t)]cˆPL + (nXc(t) +mY c(t))
.
Solve the equation for λ0. It follows
λ0 =
nX(t)a+mY (t)b+ (nXc(t) +mY c(t))
[nX(t) +mY (t)]cˆPL + (nXc(t) +mY c(t))− 1 .
Consider that all patients in Example 4 have exponential survival time of
various intensity (a, b and 1 respectively), the law of large number guarantees
nX(t)
n+m
→ pe−at, mY (t)
n+m
→ (1− p)e−bt and nXc(t) +mY c(t)
n+m
→ e−t.
Hence the limit of λ0, the estimated hazard for a control group patient living
within the infinitestimal time interval (t, t+ dt) is
λ0 ≈ pe
−ata+ (1− p)e−btb+ e−t
(pe−at + (1− p)e−bt)c∗PL + e−t
.
This is formula (11).
5.2 Inequalities for different versions of the combined
treatment effect
We have investigated various definitions of the overall treatment effect for a
mixed patient population. Here we are going to demonstrate the quantita-
tive relationship between these definitions assuming the simplest modelling
setup as was described in Example 1. That is, the treatment group indicator
Z ∼ Bernoulli(q) is the only covariate for the proportional hazard models.
The survival times of the enrolled patients follow proportional hazard models
with hazard ratios a = eα and b = eβ respectively for trial 1 and 2. The ratio
of the sample sizes of the two trials always equals p : (1 − p). We have the
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following candidates for the definition of the overall (log) hazard ratio:
i) θL = pα + (1− p)β,
ii) cL = pa+ (1− p)b,
iii) c∗PL as the solution to equation (8),
iv) c∗HM , the harmonic mean of a and b as was defined in (16).
Proposition 3. For arbitrary a < b, q ∈ (0, 1) and p ∈ (0, 1), the following
inequalities always holds true:
1) a < c∗HM < exp(θL) < cL < b;
2) a < c∗PL < cL < b.
Proof. The harmonic mean c∗HM > a is trivial.
To compare c∗HM with exp(θL), consider their ratio
exp(θL)
c∗HM
= p
(
b
a
)1−p
+ (1− p)
(a
b
)p
.
Denote the above ratio by R(a, b) and calculate
∂R(a, b)
∂b
= p(1− p)
(a
b
)p
(1/a− 1/b) > 0,∀a < b.
Combined with the fact that R(a, b = a) = 1, it indicates R(a, b) > 1 for any
b > a therefore we proved
c∗HM < exp(θL).
Using the Jensen’s inequality with the convex function g(x) = ex, it is easy
to prove that
exp(θL) = e
pa+(1−p)b < pea + (1− p)eb = cL.
It is also trivial to see that the algebraic mean cL < b.
For simplicity, denote the integrand in (8) by f(u, a, b, c). To compare a and
c∗PL, note that
f(u, a, b, c = a) =
(1− q)e−u + pqae−au + (1− p)qbe−bu
(1− q)e−u + pqae−au + (1− p)qae−bu · e
−u > e−u,∀a < b.
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Hence
∫∞
0
f(u, a, b, a)du > 1. To achieve an equality in (8), one must have
the solution c∗PL > a because f(u, a, b, c) is decreasing with respect to c.
To compare c∗PL with cL, observe that
[pqae−au + (1− p)qbe−bu]− [pqcLe−au + (1− p)qcLe−bu]
= p(1− p)q(a− b)(e−au − e−bu) < 0
Therefore f(u, a, b, cL) < e
−u and equivalently
∫∞
0
f(u, a, b, c∗PL)du < 1. To
achieve an equality in (8), one must have c∗PL < cL. 
One may also be tempted to find a fixed order for c∗HM vs c
∗
PL and c
∗
PL vs
exp(θL). However, close examination of the algebraic definitions implies that
the result of these comparisons depend on the values of the parameters. The
rule of thumb is, c∗HM < c
∗
PL < exp(θL) for most a < b < 1 of practical
importance. Only when a is extremely small (typically smaller than 0.2) one
can observe exp(θL) < c
∗
PL. When 1 < a < b, c
∗
PL and c
∗
HM are pretty close
to each other and Proposition 3 indicates that c∗HM < exp(θL). Here is an
example demonstrating the relationships of these estimators.
Example 6. Let p = 0.5, q = 0.5. We plotted the percentage differences
between the three estimators in Figure 2. The second estimator in the list is
always the basis for comparison.
Note that when a assumes a decent value, e.g., any number greater than 0.5,
the linear log hazard ratio estimate θˆL always leads to a conservative defi-
nition for the overall treatment effect compared the limit of the MPLE c∗PL
or the limit of the MLE c∗HM . The bias in exp(θL) can be higher than 38%
depending on the distance between a and b. Table 1 are the exact values of
the overall hazard ratios defined for various combinations of a, b:
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